Welcome to our dedicated page for Sera Prognostics SEC filings (Ticker: SERA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sera Prognostics, Inc. filings document a public women's health diagnostics company focused on pregnancy biomarker information and the PreTRM® Test. Recent 8-K reports furnish quarterly and annual financial results, business highlights, investor presentations and Regulation FD disclosures tied to PRIME study publications and PreTRM clinical evidence.
Its proxy materials describe annual meeting matters, corporate governance, shareholder voting items, strategic priorities, capital allocation and commercial progress. The filing record also covers securities-law treatment of furnished press releases and exhibits related to results, clinical data and market-adoption updates.
SERA PROGNOSTICS, INC. Chief Commercial Officer Dyaarl Lee Anderson Jr. reported selling 4,739 shares of Class A Common Stock at a weighted average price of $2.01 per share. According to the disclosure, these shares were sold to cover tax withholding obligations from vesting restricted stock units and the transaction was mandated by the company’s sell-to-cover requirement, rather than being a discretionary trade. Following the sale, Anderson directly holds 77,998 shares.
Sera Prognostics, Inc. Chief Financial Officer Austin Aerts reported an open-market sale of 2,037 shares of Class A common stock at a weighted average price of $2.01 per share. According to the disclosure, these shares were sold solely to cover tax withholding obligations from vesting restricted stock units under a mandatory sell-to-cover policy, rather than as a discretionary trade. Following this tax-related sale, Aerts directly holds 301,190 shares of Sera Prognostics common stock.
SERA PROGNOSTICS, INC. Chief Executive Officer and director Zhenya Lindgardt reported a sale of 6,990 shares of Class A Common Stock at a weighted average price of $2.01 per share. According to the disclosure, this was a mandated “sell to cover” transaction to satisfy tax withholding on vesting restricted stock units, not a discretionary trade. After the sale, Lindgardt directly holds 865,009 shares, indicating the sale represents a very small portion of the reported holdings.
SERA PROGNOSTICS, INC. Chief Medical Officer Tiffany Eul Davis reported a small sale of Class A Common Stock tied to tax withholding on vested equity. She sold 362 shares on June 11, 2026 at a weighted average price of $2.01 per share as part of a block trade.
According to the disclosure, this transaction was a mandated “sell to cover” to satisfy tax withholding obligations from restricted stock unit vesting and was not a discretionary sale. After this sale, she directly holds 92,075 shares of SERA common stock.
SERA PROGNOSTICS, INC. General Counsel Benjamin Jackson reported an open-market sale of 2,179 shares of Class A Common Stock at a weighted average price of $2.01 per share. According to the disclosure, this sale was mandated to cover tax withholding on vesting restricted stock units through a required “sell to cover” arrangement, rather than a discretionary trade. Following the transaction, Jackson holds 161,756 shares directly.
SERA submitted a Form 144 notice reporting proposed sales of Class A Common stock tied to restricted stock unit vesting. The filing lists a sale method tied to Restricted Stock Unit Vesting with an effective date of 06/11/2026. It also discloses prior sales by Austin Aerts on 03/11/2026 and 06/09/2026.
SERA submitted a Rule 144 notice relating to Class A Common stock. The filing lists 6,990 shares tied to Restricted Stock Unit Vesting scheduled 06/11/2026 and records recent dispositions by Zhenya Lindgardt of 2,973 shares on 03/11/2026 and 20,755 shares on 06/09/2026.
SERA notice: a Form 144 lists 2,179 Class A Common shares tied to restricted stock unit vesting scheduled 06/11/2026 for sale through Morgan Stanley Smith Barney LLC on NASDAQ. The filing also shows a prior disposition of 1,027 shares on 03/11/2026 (listed with 2,096 in the same row).